Longitudinal computed tomography-based delta-radiomics of visceral adipose tissue predicts infliximab secondary loss of response in Crohn’s disease patients

Figure 4 Calibration and clinical utility of models for predicting secondary loss of response to infliximab in patients with Crohn’s disease. A and B: Calibration plots for clinical model, delta-radiomics model and combined model in the training cohort (A) and the validation cohort (B); C and D: Decision curve analysis for these three models in the training cohort (C) and the validation cohort (D).